MedPath

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Phase 3
Completed
Conditions
lcerateive Colotis
Registration Number
JPRN-jRCT2080222598
Lead Sponsor
AbbVie GK
Brief Summary

Safety and efficacy of adalimumab in pediatric patients were evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
All
Target Recruitment
101
Inclusion Criteria

Diagnosis of Ulcerative Colitis (UC) for at least 12 weeks prior to screening, confirmed by endoscopy with biopsy.
Active ulcerative colitis with a Mayo Score of 6 - 12 points and endoscopy subscore of 2 - 3 despite concurrent treatment with oral corticosteroids or immunosuppressants or both.

Exclusion Criteria

Subject with Crohn's disease (CD) or indeterminate colitis (IC).
Current diagnosis of fulminant colitis and/or toxic megacolon.
Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
Chronic recurring infections or active Tuberculosis (TB).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety<br>efficacy<br>pharmacokinetics<br>Percentage of participants who achieve clinical remission per partial Mayo score (PMS) [ Time Frame: Week 8 ]<br>Percentage of participants who responded at Week 8 per PMS and achieve clinical remission per Mayo score [ Time Frame: Week 52 ]
Secondary Outcome Measures
NameTimeMethod
safety<br>efficacy<br>pharmacokinetics<br>Percentage of participants who achieve mucosal healing [ Time Frame: Week 52 ]<br>Percentage of participants in Mayo clinical response in Week 8 responders [ Time Frame: Week 52 ]<br>Percentage of participants who achieve Mayo clinical remission in Week 8 remitters [ Time Frame: Week 52 ]<br>Percentage of participants receiving corticosteroid at Baseline who have discontinued corticosteroid prior to Week 52 and are in Mayo clinical remission in Week 8 responders [ Time Frame: Week 52 ]<br>Partial Mayo Score, Mayo endoscopy subscore
© Copyright 2025. All Rights Reserved by MedPath